Aisling Capital is a private equity firm that specializes in growth equity investments in the healthcare sector. The firm focuses on providing capital to commercial-stage companies with a track record of revenue generation. Aisling Capital partners with management teams to help drive value creation through strategic guidance and operational support.

Aisling Capital

Renaissance Venture Capital focuses on providing capital and connecting venture capital firms with innovation companies and established businesses to support economic growth, self-described.

Renaissance Venture Capital

Aisling Capital believes the next decade will be marked by a revolution in healthcare driven by new therapeutics generated by biotechnology. The completion of the human genome has given scientists new insights into the causes of human disease. These insights, combined with the past 20 years of developments in the biotechnology industry, are leading to rapid expansion of novel approaches toward the diagnosis, prevention, and treatment of life-threatening illnesses. These advances have led to an ever-increasing demand for capital to complete the development and commercialization of new therapeutics. Our goal is to support the leading global healthcare companies that are building on these technical and medical breakthroughs to commercialize new healthcare products.

Monte Rosa Therapeutics

Elevation Oncology

Intercept Pharmaceuticals

Nuvation Bio

Poseida Therapeutics

Reneo Pharmaceuticals

Biohaven Pharmaceutical

Biomea Fusion

BridgeBio

Bristol-Myers Squibb

Syros Pharmaceuticals

T2 Biosystems

Talaris Therapeutics

Asensus Surgical

Verona Pharma

ViewRay

Aclaris Therapeutics

ADMA Biologics

Arcus Biosciences

Atreca

Avrobio

Metric
Company Name	Aisling Capital	Renaissance Venture Capital
Symbol
MSH ID	COM:AISLINGCAPITAL	COM:RENVCF
Market	PRIVATE	PRIVATE
Sector	Financial Services & Finance	Financial Services & Finance
Industry	Private Equity	Venture Capital
Country	US	US
Stage
Employee Count	19
Website	aislingcapital.com	renvcf.com
LinkedIn	aisling-capital
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	1.27K
Web Traffic Growth	-0.74
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:AISLINGCAPITAL

Aisling Capital

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue